---
id: apa-major-depressive-disorder-2024
title: "APA 2024 Practice Guideline: Major Depressive Disorder in Adults"
short_title: "APA MDD 2024"

organization: American Psychiatric Association
collaborators: null
country: US
url: https://www.psychiatry.org/guidelines
doi: null
pmid: null
open_access: true

specialty: psychiatry
guideline_type: clinical-practice
evidence_system: APA
conditions:
  - major depressive disorder
  - MDD
  - depression
tags:
  - SSRIs
  - psychotherapy
  - TRD
  - ketamine
  - ECT

publication_date: 2024-09-01
previous_version_date: 2019-10-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 APA clinical practice guideline on the treatment of major depressive disorder (MDD) in adults.

## Key Recommendations

### Initial Assessment
- Comprehensive psychiatric evaluation including suicide risk assessment.
- Assessment of severity (PHQ-9), functional impairment, comorbidities, prior treatment history.
- Screen for bipolar disorder before initiating antidepressant monotherapy.

### Treatment Options

#### Mild-to-Moderate MDD
- **Psychotherapy**: CBT, interpersonal therapy (IPT), behavioral activation are effective.
- **Pharmacotherapy**: SSRIs/SNRIs are first-line.
- Monotherapy with either is acceptable; combination may be considered.

#### Moderate-to-Severe MDD
- **Combination** of pharmacotherapy + psychotherapy is generally preferred.

### Pharmacotherapy

#### First-Line
- **SSRIs**: Sertraline, escitalopram, fluoxetine, paroxetine, citalopram.
- **SNRIs**: Venlafaxine, duloxetine.
- Select based on side effect profile, patient preference, cost, and comorbidities.

#### Other Options
- **Bupropion**: Helpful if fatigue, weight gain, or sexual dysfunction concerns.
- **Mirtazapine**: Sedating; useful for insomnia, appetite concern.
- **TCAs, MAOIs**: Reserved for refractory cases.

### Inadequate Response (After 4-8 Weeks at Adequate Dose)
- Switch antidepressant (within or across class).
- Augment with: atypical antipsychotic (aripiprazole, brexpiprazole, cariprazine, quetiapine), lithium, bupropion, buspirone.

### Treatment-Resistant Depression (TRD)
- **Esketamine (Spravato)**: Intranasal, REMS program. For TRD as adjunct to oral antidepressant.
- **IV Ketamine**: Off-label; rapid antidepressant effects.
- **ECT (Electroconvulsive Therapy)**: Highly effective for severe/refractory MDD, catatonia, high suicide risk.
- **TMS (Transcranial Magnetic Stimulation)**: Non-invasive neuromodulation.

### Maintenance
- Continue effective treatment for â‰¥6-12 months after remission; longer for recurrent MDD.

### Safety Monitoring
- Monitor for suicidal ideation, especially early in treatment in younger patients.
